![Inaugural Zero-K Run Raises Awareness for CMT and CMTRF](https://cmtrf.org/wp-content/uploads/2024/07/Gary-Berg-Zero-k-e1721404092192-1080x675.png)
![Inaugural Zero-K Run Raises Awareness for CMT and CMTRF](https://cmtrf.org/wp-content/uploads/2024/07/Gary-Berg-Zero-k-e1721404092192-1080x675.png)
![CMT Research Foundation to Launch Grant Program to Support Young Investigators Working on CMT](https://cmtrf.org/wp-content/uploads/2024/07/Researcher-1045x675.png)
CMT Research Foundation to Launch Grant Program to Support Young Investigators Working on CMT
The CMT Research Foundation announced that at its annual Global CMT Research Convention this September, it will host a Young Researcher Innovation Forum for CMT Research. The program will introduce the Young Researcher Innovation Grant and provide a platform to...![Augustine Therapeutics Raises $18.5 Million in a Series A First Closing](https://cmtrf.org/wp-content/uploads/2023/03/Current_Augustine-Tx_35mm-Logo-1.png)
Augustine Therapeutics Raises $18.5 Million in a Series A First Closing
The Charcot-Marie-Tooth Research Foundation participated in the $18.5 million Series A funding round recently announced by Augustine Therapeutics. The financing was led by Asabys Partners, with the participation of Eli Lilly & Company, CMTRF, and current investors...![NMD Pharma Receives FDA Clearance to Initiate Clinical Trial of NMD670 for CMT](https://cmtrf.org/wp-content/uploads/2024/04/NMD_Pharma_3-1080x327.png)
NMD Pharma Receives FDA Clearance to Initiate Clinical Trial of NMD670 for CMT
NMD Pharma recently announced that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of NMD670 in patients living with CMT types 1 and 2. NMD670 is a...![CMTRF at the 2024 American Society of Gene and Cell Therapy Conference](https://cmtrf.org/wp-content/uploads/2024/05/ASGCT-1080x675.png)